BioSpace News Archive

Sparta Science, the developer of a machine learning-based Movement Health platform, was recently awarded an AFWERX Small Business Technology Transfer Research (STTR) Phase I contract by the United States Air Force (USAF) to develop an objective, scalable decision support tool that improves the efficiency of rehabilitation and performance optimization experts.

Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare.

The Olympus POWERSEAL™ 5mm Curved Jaw Sealer/Divider, Double-Action won the 2022 GOOD DESIGN® Award within the Medical Category.

DelveInsight’s ‘Methicillin-Resistant Staphylococcus aureus Infection Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline methicillin-resistant Staphylococcusaureus infection therapies in various stages of clinical development.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus).

IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) will announce its fourth-quarter and full-year 2022 financial results before the market opens on Friday, February 10, 2023.

ReLive Biotechnologies, Ltd., taking over the global patent rights of its flagship products “Spherox” and “Chondrosphere”.

InnoCare Pharma announced that the latest clinical result of FGFR inhibitor gunagratinib for the treatment of cholangiocarcinoma was presented at 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

HBM Alpha Therapeutics, Inc. announced that it completed seed financing to advance its leading programs, novel antibody therapies to treat congenital adrenal hyperplasia and polycystic ovary syndrome, with the lead candidate currently in IND-enabling stage.

Genelux Corporation announced the pricing of its initial public offering of 2,500,000 shares of its common stock at a price to the public of $6.00 per share, for total gross proceeds of approximately $15.0 million, before deducting underwriting discounts and commissions and offering expenses.